How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Cancer Res Treat. 2013;45(3):178-185. Published online 2013 Sep 30 DOI: https://doi.org/10.4143/crt.2013.45.3.178
Citations to this article as recorded by 
Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review
Aye Myat Thi, Sandar Tin Tin, Mark McKeage, J. Mark Elwood
Targeted Oncology.2020; 15(3): 279. CrossRef
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Research and Treatment.2019; 51(1): 169. CrossRef
EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand
Mark McKeage, Mark Elwood, Sandar Tin Tin, Prashannata Khwaounjoo, Phyu Aye, Angie Li, Karen Sheath, Phillip Shepherd, George Laking, Nicola Kingston, Christopher Lewis, Donald Love
Targeted Oncology.2017; 12(5): 663. CrossRef
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, Nicola Normanno, Laksmi Wulandari, Konstantin Laktionov, Achmad Hudoyo, Yong He, Yi-Ping Zhang, Meng-Zhao Wang, Chien Ying Liu, Marianne Ratcliffe, Rose McCormack, Martin Reck
Lung Cancer.2017; 113: 37. CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500. CrossRef
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo
Cancer Research and Treatment.2016; 48(1): 88. CrossRef
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Sam Santhosh, Prasanna Kumar, Vedam Ramprasad, Amitabha Chaudhuri
Future Oncology.2015; 11(2): 279. CrossRef
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation
Bhumsuk Keam, Soo Jin Lee, Tae Min Kim, Jin Chul Paeng, Se-Hoon Lee, Dong-Wan Kim, Yoon Kyung Jeon, Doo Hyun Chung, Keon Wook Kang, June-Key Chung, Dae Seog Heo
Journal of Thoracic Oncology.2015; 10(8): 1189. CrossRef
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
Sung Hoon Sim, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2135. CrossRef